Skip to main content
SpringerLink
Log in

UGDP CONTROVERSY CONTINUES WHILE FDA TAKES OFFICIAL ACTION

  • Newsletter Article
  • Published:
InPharma

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

UGDP CONTROVERSY CONTINUES WHILE FDA TAKES OFFICIAL ACTION. Inpharma Wkly. 12, 4–5 (1975). https://doi.org/10.1007/BF03287960

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03287960

Keywords

Search

Navigation